Plasminogen activator inhibitor-1 in aging

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 6, 2014, Pages 652-659

  Yamamoto, Koji ^a   Takeshita, Kyosuke ^a   Saito, Hidehiko ^b  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

fibrosis; metabolic syndrome; PAI 1; thrombosis; vascular sclerosis

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

AGING; ANIMAL; BLOOD; FIBRINOLYSIS; FIBROSIS; HUMAN; METABOLIC SYNDROME X; METABOLISM; PHYSIOLOGY; THROMBOSIS;

AGING; ANIMALS; FIBRINOLYSIS; FIBROSIS; HUMANS; METABOLIC SYNDROME X; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS;

EID: 84939884913     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1384635     Document Type: Article

References (100)

1. Tracy R. P., Bovill E. G. Thrombosis and cardiovascular risk in the elderly. Arch Pathol Lab Med: 1992; 116 12 1307 1312
2. Wilkerson W. R., Sane D. C. Aging and thrombosis. Semin Thromb Hemost: 2002; 28 6 555 568
3. Kiechl S., Willeit J.; Bruneck Study Group. The natural course of atherosclerosis. Part II: vascular remodeling. Arterioscler Thromb Vasc Biol: 1999; 19 6 1491 1498
4. Koster T., Rosendaal F. R., Reitsma P. H., van der Velden P. A., Briët E., Vandenbroucke J. P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost: 1994; 71 6 719 722
5. Abbate R., Prisco D., Rostagno C., Boddi M., Gensini G. F. Age-related changes in the hemostatic system. Int J Clin Lab Res: 1993; 23 1 1 3
6. Hashimoto Y., Kobayashi A., Yamazaki N., Sugawara Y., Takada Y., Takada A. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity. Thromb Res: 1987; 46 5 625 633
7. Loskutoff D. J., Sawdey M., Mimuro J. Type 1 plasminogen activator inhibitor. In: Coller B., ed. Progress in Hemostasis and Thrombosis. Philadelphia, PA WB Saunders Company: 1988; 87 115
8. Yamamoto K., Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol: 1998; 68 4 371 385
9. Yamamoto K., Takeshita K., Kojima T., Takamatsu J., Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res: 2005; 66 276 285
10. Stefansson S., Lawrence D. A. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature: 1996; 383 6599 441 443
11. Heymans S., Luttun A., Nuyens D., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med: 1999; 5 10 1135 1142
12. Eren M., Gleaves L. A., Atkinson J. B., King L. E., Declerck P. J., Vaughan D. E. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost: 2007; 5 7 1500 1508
13. Loskutoff D. J. Regulation of PAI-1 gene expression. Fibrinolysis: 1991; 5 197 206
14. Sawdey M. S., Loskutoff D. J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β J Clin Invest: 1991; 88 4 1346 1353
15. Yamamoto K., Loskutoff D. J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest: 1996; 97 11 2440 2451
16. Samad F., Yamamoto K., Loskutoff D. J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor- α and lipopolysaccharide. J Clin Invest: 1996; 97 1 37 46
17. Yamamoto K., Takeshita K., Shimokawa T., et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A: 2002; 99 2 890 895
18. Takeshita K., Hayashi M., Iino S., et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol: 2004; 164 2 449 456
19. Naito M., Funaki C., Hayashi T., et al. Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis: 1992; 96 2-3 227 234
20. Smith E. B., Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis: 1990; 84 2-3 173 181
21. Eitzman D. T., Westrick R. J., Xu Z., Tyson J., Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood: 2000; 96 13 4212 4215
22. Arenillas J. F., Alvarez-Sabín J., Molina C. A., et al. Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke: 2008; 39 5 1456 1463
23. Juhan-Vague I., Alessi M. C., Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia: 1991; 34 7 457 462
24. Schneiderman J., Sawdey M. S., Keeton M. R., et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A: 1992; 89 15 6998 7002
25. Chomiki N., Henry M., Alessi M. C., Anfosso F., Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost: 1994; 72 1 44 53
26. Cristofalo V. J., Pignolo R. J. Molecular markers of senescence in fibroblast-like cultures. Exp Gerontol: 1996; 31 1-2 111 123
27. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol: 2007; 8 9 729 740
28. Rerolle J. P., Hertig A., Nguyen G., Sraer J. D., Rondeau E. P. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int: 2000; 58 5 1841 1850
29. Oikawa T., Freeman M., Lo W., Vaughan D. E., Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int: 1997; 51 1 164 172
30. Yamamoto K., Loskutoff D. J. The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol: 1997; 151 3 725 734
31. Zaman A. K., Fujii S., Sawa H., et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation: 2001; 103 25 3123 3128
32. Kaikita K., Fogo A. B., Ma L., Schoenhard J. A., Brown N. J., Vaughan D. E. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation: 2001; 104 7 839 844
33. Blasi F., Vassalli J. D., Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol: 1987; 104 4 801 804
34. Olman M. A., Mackman N., Gladson C. L., Moser K. M., Loskutoff D. J. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest: 1995; 96 3 1621 1630
35. Eitzman D. T., McCoy R. D., Zheng X., et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest: 1996; 97 1 232 237
36. Vaughan D. E., Lazos S. A., Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest: 1995; 95 3 995 1001
37. Koh K. K., Ahn J. Y., Han S. H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol: 2003; 42 5 905 910
38. Okada H., Watanabe Y., Kikuta T., et al. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol: 2004; 15 9 2404 2413
39. Brown N. J., Agirbasli M. A., Williams G. H., Litchfield W. R., Vaughan D. E. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension: 1998; 32 6 965 971
40. Matsushita H., Chang E., Glassford A. J., Cooke J. P., Chiu C. P., Tsao P. S. eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. Circ Res: 2001; 89 9 793 798
41. Hayashi T., Matsui-Hirai H., Miyazaki-Akita A., et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci U S A: 2006; 103 45 17018 17023
42. Bouchie J. L., Hansen H., Feener E. P. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol: 1998; 18 11 1771 1779
43. Katoh M., Egashira K., Mitsui T., Chishima S., Takeshita A., Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol: 2000; 32 1 73 83
44. Weisberg A. D., Albornoz F., Griffin J. P., et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol: 2005; 25 2 365 371
45. Boe A. E., Eren M., Murphy S. B., et al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation: 2013; 128 21 2318 2324
46. Juhan-Vague I., Pyke S. D., Alessi M. C., Jespersen J., Haverkate F., Thompson S. G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation: 1996; 94 9 2057 2063
47. Hamsten A., Wiman B., de Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med: 1985; 313 25 1557 1563
48. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet: 1987; 2 8549 3 9
49. Collet J. P., Montalescot G., Vicaut E., et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation: 2003; 108 4 391 394
50. Iacoviello L., Agnoli C., De Curtis A., et al. Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study. BMJ Open: 2013; 3 11 e003725
51. Eriksson P., Kallin B., van 't Hooft F. M., Båvenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A: 1995; 92 6 1851 1855
52. Hultman K., Björklund U., Hansson E., Jern C. Potentiating effect of endothelial cells on astrocytic plasminogen activator inhibitor type-1 gene expression in an in vitro model of the blood-brain barrier. Neuroscience: 2010; 166 2 408 415
53. Nagai N., Suzuki Y., Van Hoef B., Lijnen H. R., Collen D. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost: 2005; 3 7 1379 1384
54. Tjärnlund-Wolf A., Brogren H., Lo E. H., Wang X. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke: 2012; 43 10 2833 2839
55. Dohgu S., Takata F., Matsumoto J., et al. Autocrine and paracrine up-regulation of blood-brain barrier function by plasminogen activator inhibitor-1. Microvasc Res: 2011; 81 1 103 107
56. Soeda S., Koyanagi S., Kuramoto Y., et al. Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system. Thromb Haemost: 2008; 100 6 1014 1020
57. McGill J. B., Schneider D. J., Arfken C. L., Lucore C. L., Sobel B. E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes: 1994; 43 1 104 109
58. Vague P., Juhan-Vague I., Aillaud M. F., et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism: 1986; 35 3 250 253
59. Brouwers M. C., Govers-Riemslag J., Schalkwijk C. G., et al. Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E. Thromb Res: 2008; 122 4 466 472
60. Shimomura I., Funahashi T., Takahashi M., et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med: 1996; 2 7 800 803
61. Festa A., D'Agostino R. Jr, Tracy R. P., Haffner S. M.; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes: 2002; 51 4 1131 1137
62. Samad F., Loskutoff D. J. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med: 1996; 2 5 568 582
63. Ma L. J., Mao S. L., Taylor K. L., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes: 2004; 53 2 336 346
64. Gabriely I., Yang X. M., Cases J. A., Ma X. H., Rossetti L., Barzilai N. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis: 2002; 160 1 115 122
65. Samad F., Pandey M., Bell P. A., Loskutoff D. J. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med: 2000; 6 8 680 692
66. Sobel B. E., Hardison R. M., Genuth S., et al. BARI 2D Investigators. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation: 2011; 124 6 695 703
67. Nishimura S., Manabe I., Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Discov Med: 2009; 8 41 55 60
68. Uchida Y., Takeshita K., Yamamoto K., et al. Stress augments insulin resistance and prothrombotic state: role of visceral adipose-derived monocyte chemoattractant protein-1. Diabetes: 2012; 61 6 1552 1561
69. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest: 1995; 95 5 2409 2415
70. Samad F., Uysal K. T., Wiesbrock S. M., Pandey M., Hotamisligil G. S., Loskutoff D. J. Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A: 1999; 96 12 6902 6907
71. Samad F., Yamamoto K., Pandey M., Loskutoff D. J. Elevated expression of transforming growth factor-β in adipose tissue from obese mice. Mol Med: 1997; 3 1 37 48
72. Pralong G., Calandra T., Glauser M-P., et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost: 1989; 61 3 459 462
73. Green J., Doughty L., Kaplan S. S., Sasser H., Carcillo J. A. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost: 2002; 87 2 218 223
74. Emeis J. J., Brouwer A., Barelds R. J., Horan M. A., Durham S. K., Kooistra T. On the fibrinolytic system in aged rats, and its reactivity to endotoxin and cytokines. Thromb Haemost: 1992; 67 6 697 701
75. Yamamoto K., Shimokawa T., Yi H., et al. Aging accelerates endotoxin-induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol: 2002; 161 5 1805 1814
76. Rosas G. O., Zieman S. J., Donabedian M., Vandegaer K., Hare J. M. Augmented age-associated innate immune responses contribute to negative inotropic and lusitropic effects of lipopolysaccharide and interferon gamma. J Mol Cell Cardiol: 2001; 33 10 1849 1859
77. Newland J. R., Haire W. D. Elevated plasminogen activator inhibitor levels found in patients with malignant conditions. Am J Clin Pathol: 1991; 96 5 602 604
78. Prendergast G. C., Diamond L. E., Dahl D., Cole M. D. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol Cell Biol: 1990; 10 3 1265 1269
79. Boccaccio C., Sabatino G., Medico E., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature: 2005; 434 7031 396 400
80. Kristensen P., Pyke C., Lund L. R., Andreasen P. A., Dano K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry: 1990; 93 6 559 566
81. Pyke C., Kristensen P., Ralfkiaer E., Eriksen J., Dano K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res: 1991; 51 15 4067 4071
82. Pedersen H., Brünner N., Francis D., et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res: 1994; 54 17 4671 4675
83. Nekarda H., Schmitt M., Ulm K., et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res: 1994; 54 11 2900 2907
84. Kuhn W., Schmalfeldt B., Reuning U., et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer: 1999; 79 11-12 1746 1751
85. Kobayashi H., Fujishiro S., Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res: 1994; 54 24 6539 6548
86. Dano K., Andreasen P. A., Grondahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res: 1985; 44 139 266
87. Bajou K., Noël A., Gerard R. D., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med: 1998; 4 8 923 928
88. Bajou K., Masson V., Gerard R. D., et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol: 2001; 152 4 777 784
89. Rosengren A., Hawken S., Ôunpuu S., et al. INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet: 2004; 364 9438 953 962
90. Räikkönen K., Lassila R., Keltikangas-Järvinen L., Hautanen A. Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Arterioscler Thromb Vasc Biol: 1996; 16 3 363 367
91. Supiano M. A., Hogikyan R. V., Sidani M. A., Galecki A. T., Krueger J. L. Sympathetic nervous system activity and alpha-adrenergic responsiveness in older hypertensive humans. Am J Physiol: 1999; 276 3 Pt 1 E519 E528
92. Larsson P. T., Wiman B., Olsson G., Angelin B., Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost: 1990; 63 3 482 487
93. Vulin A. I., Stanley F. M. Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biol Chem: 2004; 279 24 25172 25178
94. Konkle B. A., Schuster S. J., Kelly M. D., et al. Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone. Blood: 1992; 79 10 2636 2642
95. Yamamoto K., Shimokawa T., Yi H., et al. Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse. Blood: 2002; 100 12 4011 4018
96. Takeshita K., Yamamoto K., Ito M., et al. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, Klotho mouse. Semin Thromb Hemost: 2002; 28 6 545 554
97. Goldstein S., Moerman E. J., Fujii S., Sobel B. E. Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome. J Cell Physiol: 1994; 161 3 571 579
98. Mu X. C., Higgins P. J. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J Cell Physiol: 1995; 165 3 647 657
99. Kunz C., Pebler S., Otte J., von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res: 1995; 23 18 3710 3717
100. Kortlever R. M., Higgins P. J., Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol: 2006; 8 8 877 884